Axial Spondyloarthritis Treatment Market Trends, Growth, Report 2027

Summary

Report Description

The global axial spondyloarthritis treatment market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include rising incidence of axial spondyloarthritis and increasing public awareness of the disease are propelling the growth of the market. Axial spondyloarthritis is a chronic inflammatory condition that impacts the axial skeleton. The person undergoes from severe discomfort, stiffness in the back area, and fatigue because of it. The other factors supporting the market’s growth are, growing world population, increasing research activities, surge in number of patients, large number of clinical trials, rising product innovation and development, significant investment in research and development, rising per capita health care expenditure, increasing prevalence of axial spondyloarthritis, growing number of mergers and acquisitions, and rising emphasis of several authorities on improving existing healthcare infrastructure.

Surge in Incidences of Axial Spondylarthritis

The increasing prevalence of axial spondylarthritis, across the globe are bolstering the growth of the market. The cause of axial spondylarthritis is not known but after several research it is assumed that it is caused due to the exposure of genes to certain bacteria, virus, or other triggers. Patients undergo serious discomfort such as stiffness in the affected part, and fatigue. Not only elderly population but younger generation are also prone to the disease. Therefore, these factors are bolstering the growth of the market globally. According to a cited study, in the U.S., about 2.7 million Americans or more are affected by axial spondyloarthritis (axSpA).

Increase in the Number of Approved Biosimilars

According to the World Health Organization (WHO), Biosimilars refers as a biotherapeutic product which is similar in terms of safety, quality, and efficacy to an already licensed original biotherapeutic product. Biosimilars are the biologic drugs which helps in treating diseases such as axial spondylarthritis. They are very effective in patients and have replaced originator drugs due to the greater accessibility. In the past few years, there is a surge in the number of approved biosimilars for the treatment of axial spondylarthritis, which is augmenting the growth of the market, globally. For instance, in 2020 and 2021, the U.S. Food and Drug Administration approved three novel products, i.e., Xeljanz, Taltz, and Cosentyx, to treat individuals with axial spondyloarthritis

Increasing R&D Activities

Rise in research and development (R&D) activities in molecular and immunologic field are propelling the growth of the market. Owing to the increase in research activities, the advent of novel biologic agents such as tumor necrosis factor (TNF) inhibitors, IL-23 and interleukin (IL)-17 inhibitors are surging. For instance, in 2022, UCB, a global biopharmaceutical company, announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints. BE MOBILE 1 is the primary study to measure the effectiveness and safety of bimekizumab in adults suffering from active non-radiographic axial spondyloarthritis (nr-axSpA). Moreover, the rising investments for the research activities by government is facilitating the growth of the market.

Download Free Sample Report

Market Segmentation

The global axial spondyloarthritis treatment market is segmented into therapy, indication, end user and company. Based on therapy, the market is divided into anti-tumor necrosis factor (TNF) therapy, anti-interleukin (IL) therapy, and anti-janus kinase (JAK) therapy. Based on indication, the market is divided into ankylosing spondylitis and non-radiographic axial spondyloarthritis treatment. Based on end user, the market is divided into hospitals & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rise in R&D activities in the country.

Market Players

Novartis International, AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Pfizer, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., AbbVie Inc, Bristol-Myers Squibb Company, and FunPep Co., Ltd. are some of the leading companies operating in the market.

Attribute	Details
Base Year	2021
Historic Data	2017 – 2020
Estimated Year	2022
Forecast Period	2023 – 2027
Quantitative Units	Revenue in USD Million, Volume Units and CAGR for 2017-2021 and 2022-2027
Report coverage	Revenue forecast, Volume forecast company share, competitive landscape, growth factors, and trends
Segments covered	· Therapy · Indication · End User · Company
Regional scope	North America; Asia Pacific; Europe & CIS; South America; Middle East & Africa
Country scope	United States; Canada; Mexico; China; India; Japan; South Korea; Germany; France; United Kingdom; Spain; Italy; Brazil; Argentina; Colombia; South Africa; UAE; Saudi Arabia; South Africa
Key companies profiled	Novartis International, AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Pfizer, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., AbbVie Inc, Bristol-Myers Squibb Company, and FunPep Co., Ltd.
Customization scope	10% free report customization with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Report Scope:

In this report, global axial spondyloarthritis treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

· Axial Spondyloarthritis Treatment Market, By Therapy:

o Anti-Tumor Necrosis Factor (TNF) Therapy

o Anti-Interleukin (IL) Therapy

o Anti-Janus Kinase (JAK) Therapy

· Axial Spondyloarthritis Treatment Market, By Indication:

Ankylosing Spondylitis
Non-radiographic Axial Spondyloarthritis Treatment

· Axial Spondyloarthritis Treatment Market, By End User:

Hospitals & Clinics
Academic & Research Institutions
Others

· Axial Spondyloarthritis Treatment Market, By Region:

North America

United States
Canada
Mexico

Asia-Pacific

China
India
Japan
Australia
South Korea

Europe & CIS

Germany
France
United Kingdom
Spain
Italy

South America

Brazil
Argentina
Colombia

Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Axial Spondyloarthritis Treatment Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Axial Spondyloarthritis Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Axial Spondyloarthritis Treatment Market

5. Voice of Customer

6. Clinical Trial Analysis

7. Global Axial Spondyloarthritis Treatment Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Therapy (Anti-Tumor Necrosis Factor (TNF) Therapy, Anti-Interleukin (IL) Therapy, Anti-Janus Kinase (JAK) Therapy)

7.2.2. By Indication (Ankylosing Spondylitis v/s Non-radiographic Axial Spondyloarthritis Treatment)

7.2.3. By End User (Hospitals & Clinics, Academic & Research Institutions, Others)

7.2.4. By Region

7.2.5. By Company (2021)

7.3. Market Map

8. North America Axial Spondyloarthritis Treatment Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Therapy

8.2.2. By Indication

8.2.3. By End User

8.2.4. By Country

8.3. North America: Country Analysis

8.3.1. United States Axial Spondyloarthritis Treatment Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Therapy

8.3.1.2.2. By Indication

8.3.1.2.3. By End User

8.3.2. Canada Axial Spondyloarthritis Treatment Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Therapy

8.3.2.2.2. By Indication

8.3.2.2.3. By End User

8.3.3. Mexico Axial Spondyloarthritis Treatment Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Therapy

8.3.3.2.2. By Indication

8.3.3.2.3. By End User

9. Europe Axial Spondyloarthritis Treatment Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Therapy

9.2.2. By Indication

9.2.3. By End User

9.2.4. By Country

9.3. Europe: Country Analysis

9.3.1. France Axial Spondyloarthritis Treatment Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Therapy

9.3.1.2.2. By Indication

9.3.1.2.3. By End User

9.3.2. Germany Axial Spondyloarthritis Treatment Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Therapy

9.3.2.2.2. By Indication

9.3.2.2.3. By End User

9.3.3. United Kingdom Axial Spondyloarthritis Treatment Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Therapy

9.3.3.2.2. By Indication

9.3.3.2.3. By End User

9.3.4. Italy Axial Spondyloarthritis Treatment Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Therapy

9.3.4.2.2. By Indication

9.3.4.2.3. By End User

9.3.5. Spain Axial Spondyloarthritis Treatment Market Outlook

9.3.5.1. Market Size & Forecast

9.3.5.1.1. By Value

9.3.5.2. Market Share & Forecast

9.3.5.2.1. By Therapy

9.3.5.2.2. By Indication

9.3.5.2.3. By End User

10. Asia-Pacific Axial Spondyloarthritis Treatment Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Therapy

10.2.2. By Indication

10.2.3. By End User

10.2.4. By Country

10.3. Asia-Pacific: Country Analysis

10.3.1. China Axial Spondyloarthritis Treatment Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Therapy

10.3.1.2.2. By Indication

10.3.1.2.3. By End User

10.3.2. India Axial Spondyloarthritis Treatment Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Therapy

10.3.2.2.2. By Indication

10.3.2.2.3. By End User

10.3.3. Japan Axial Spondyloarthritis Treatment Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Therapy

10.3.3.2.2. By Indication

10.3.3.2.3. By End User

10.3.4. South Korea Axial Spondyloarthritis Treatment Market Outlook

10.3.4.1. Market Size & Forecast

10.3.4.1.1. By Value

10.3.4.2. Market Share & Forecast

10.3.4.2.1. By Therapy

10.3.4.2.2. By Indication

10.3.4.2.3. By End User

10.3.5. Australia Axial Spondyloarthritis Treatment Market Outlook

10.3.5.1. Market Size & Forecast

10.3.5.1.1. By Value

10.3.5.2. Market Share & Forecast

10.3.5.2.1. By Therapy

10.3.5.2.2. By Indication

10.3.5.2.3. By End User

11. South America Axial Spondyloarthritis Treatment Market Outlook

11.1. Market Size & Forecast

11.1.1. By Value

11.2. Market Share & Forecast

11.2.1. By Therapy

11.2.2. By Indication

11.2.3. By End User

11.2.4. By Country

11.3. South America: Country Analysis

11.3.1. Brazil Axial Spondyloarthritis Treatment Market Outlook

11.3.1.1. Market Size & Forecast

11.3.1.1.1. By Value

11.3.1.2. Market Share & Forecast

11.3.1.2.1. By Therapy

11.3.1.2.2. By Indication

11.3.1.2.3. By End User

11.3.2. Argentina Axial Spondyloarthritis Treatment Market Outlook

11.3.2.1. Market Size & Forecast

11.3.2.1.1. By Value

11.3.2.2. Market Share & Forecast

11.3.2.2.1. By Therapy

11.3.2.2.2. By Indication

11.3.2.2.3. By End User

11.3.3. Colombia Axial Spondyloarthritis Treatment Market Outlook

11.3.3.1. Market Size & Forecast

11.3.3.1.1. By Value

11.3.3.2. Market Share & Forecast

11.3.3.2.1. By Therapy

11.3.3.2.2. By Indication

11.3.3.2.3. By End User

12. Middle East and Africa Axial Spondyloarthritis Treatment Market Outlook

12.1. Market Size & Forecast

12.1.1. By Value

12.2. Market Share & Forecast

12.2.1. By Therapy

12.2.2. By Indication

12.2.3. By End User

12.2.4. By Country

12.3. MEA: Country Analysis

12.3.1. South Africa Axial Spondyloarthritis Treatment Market Outlook

12.3.1.1. Market Size & Forecast

12.3.1.1.1. By Value

12.3.1.2. Market Share & Forecast

12.3.1.2.1. By Therapy

12.3.1.2.2. By Indication

12.3.1.2.3. By End User

12.3.2. Saudi Arabia Axial Spondyloarthritis Treatment Market Outlook

12.3.2.1. Market Size & Forecast

12.3.2.1.1. By Value

12.3.2.2. Market Share & Forecast

12.3.2.2.1. By Therapy

12.3.2.2.2. By Indication

12.3.2.2.3. By End User

12.3.3. UAE Axial Spondyloarthritis Treatment Market Outlook

12.3.3.1. Market Size & Forecast

12.3.3.1.1. By Value

12.3.3.2. Market Share & Forecast

12.3.3.2.1. By Therapy

12.3.3.2.2. By Indication

12.3.3.2.3. By End User

13. Market Dynamics

13.1. Drivers

13.2. Challenges

14. Market Trends & Developments

15. Competitive Landscape (Inclusive SWOT Analysis)

15.1. Novartis International, AG

15.2. Eli Lilly and Company

15.3. Johnson & Johnson

15.4. UCB S.A.

15.5. Pfizer, Inc.

15.6. Kyowa Kirin Co., Ltd.

15.7. Merck & Co., Inc.

15.8. AbbVie Inc

15.9. Bristol-Myers Squibb Company

15.10. FunPep Co., Ltd.

16. Strategic Recommendations

Figures and Tables

Frequently asked questions

What are the major drivers for the Global Axial Spondyloarthritis Treatment Market?

Growing incidences of axial spondyloarthritis, rising awareness of the disease, and extensive research and development are driving the demand for the global axial spondyloarthritis treatment market.

Who are the top players operating in the Global Axial Spondyloarthritis Treatment Market?

Novartis International, AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Pfizer, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., AbbVie Inc, Bristol-Myers Squibb Company, and FunPep Co., Ltd. are the key players operating in the global axial spondyloarthritis treatment Market.

What are the key factors hampering growth for the Global Axial Spondyloarthritis Treatment Market?

The high cost associated with biologics used to treat axial spondyloarthritis (axSpA), and adverse effects from the treatment regime may hamper the growth of the global axial spondyloarthritis treatment market.

Which region is expected to dominate the Global Axial Spondyloarthritis Treatment Market during the forecast period?

North America is expected to dominate the Global Axial Spondyloarthritis Treatment Market during the forecast period

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Axial Spondyloarthritis Treatment Market to be dominated by Growing Prevalence of Axial Spondyloarthritis through 2027

Oct, 2022

Rise in research and development activities coupled with increasing public awareness of the disease to drive the axial spondyloarthritis treatment market in the forecast period, 2023-2027.

Buy Now